TICKERNERD
Menu
LSTALSTAHealthcare · Biotechnology

LSTA Stock Forecast: Lisata Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 13 Nov 2026
$1.24
−3.13% on the day

The 2 Wall Street analysts covering Lisata Therapeutics, Inc. hold a median 12-month price target of $4 — +222.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 58 of 100 as at 13 Nov 2026 — in the upper half.

Market cap
$13.8M
Ticker Nerd rank
58/ 100
Median analyst target
$4.00
Analysts covering
2
Revenue$0.0−100.0% y/y
Operating income−$4.0M
Net income−$2.9M
Free cash flow−$2.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+20.4%
1M
+14.8%
YTD
−33.3%
1Y
−40.1%
From 52W high
−75.4%
From 52W low
+25.3%
$0.99
$5.04
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LSTA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Lisata Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Nov 2026
58/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
89
Accruals
84
Growth
81
Volatility
71
Issuance
54
Momentum
46
Value
33
Quality
33
Revisions
25

Size (89): Smaller than most of the companies we track.

Revisions (25): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

LSTA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LSTA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00Jan 26Apr 26Jul 26Oct 26LSTAHigh $4.00Median $4.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
0 Buy2 Hold0 Sell
Low $4.00Median $4.00High $4.00

The green dot is the last close — the median target sits +222.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
15 May 2026HC Wainwright & Co.DowngradeNeutral—
21 Jan 2026Brookline CapitalDowngradeHold—
21 Aug 2025HC Wainwright & Co.ReiteratesBuy—
15 July 2025Brookline CapitalMaintainsBuy—
11 Dec 2024HC Wainwright & Co.ReiteratesBuy—
21 Nov 2024HC Wainwright & Co.ReiteratesBuy—
18 Sept 2024HC Wainwright & Co.ReiteratesBuy—
13 Aug 2024HC Wainwright & Co.ReiteratesBuy—
19 July 2024HC Wainwright & Co.ReiteratesBuy—
10 July 2024HC Wainwright & Co.ReiteratesBuy—
14 June 2024HC Wainwright & Co.ReiteratesBuy—
21 May 2024HC Wainwright & Co.ReiteratesBuy—
26 Apr 2024HC Wainwright & Co.ReiteratesBuy—
25 Apr 2024HC Wainwright & Co.ReiteratesBuy—
1 Mar 2024HC Wainwright & Co.ReiteratesBuy—
4 Jan 2024HC Wainwright & Co.ReiteratesBuy—
15 Aug 2023HC Wainwright & Co.ReiteratesBuy—
25 May 2023HC Wainwright & Co.ReiteratesBuy—
31 Mar 2023HC Wainwright & Co.ReiteratesBuy—
19 Oct 2022HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

LSTA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

LSTA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 13 Nov 2026, Lisata Therapeutics, Inc. returned −40.1% against +13.4% for the S&P 500, dividends included.

LSTA vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200250Jan 26Apr 26Jul 26Oct 26LSTAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LSTA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Lisata Therapeutics, Inc. (LSTA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.7×

Cheaper than 82% of US stocks

Price / sales
138.3×

Cheaper than 3% of US stocks

Price / book
1.4×

Cheaper than 55% of US stocks

EV / EBITDA
−0.1×

Cheaper than 64% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−16426.0%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−101.7%

Higher than 13% of US stocks

Return on assets
−56.7%

Higher than 7% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Lisata Therapeutics, Inc. (LSTA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Lisata Therapeutics, Inc. has a market value of $13.8M and an enterprise value of $837K.

  • Revenue in the twelve months to 30 June 2026: $100K. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$14.6M, a −14621.0% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$12.3M.

  • Shares outstanding: 9.1M.

  • Trailing P/E: −0.7×; forward P/E: −1.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Lisata Therapeutics, Inc. employs 21 people — $5K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Nov 2026

Data provided by Twelve Data

Peers

LSTA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LSTALisata Therapeutics, Inc.$13.8M58
DYAIDyadic International, Inc.$13.1M21
QNTMQuantum BioPharma Ltd.$13.0M40
DAREDaré Bioscience, Inc.$12.7M27
PASGPassage Bio, Inc.$13.7M55
NEUPNeuphoria Therapeutics, Inc.$13.7M7
BCDABioCardia, Inc.$12.4M56

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Lisata Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LSTA news & analysis

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces MAR001 Reduces Triglycerides Without Worsening Glycemic Control in Phase 2b TYDAL-TIMI 78 Trial; Results Presented as AHA 2026 Late-Breaker and Published in The New England Journal of Medicine

GlobeNewsWire · 9 Nov 2026positive

Marea Therapeutics, a Lisata Therapeutics subsidiary, reported that Part A of the Phase 2b TYDAL-TIMI 78 trial met all objectives. MAR001 produced statistically significant placebo-adjusted triglyceride reductions of 39.1%–45.5% across three doses at Week 12, and up to 57.2% among participants with baseline triglycerides of at least 300 mg/dL.

Why it matters — The trial results concern a Lisata subsidiary’s MAR001 program and provide clinical data relevant to LSTA watchers.

Lisata adds biopharma finance veteran Jeffrey Farrow to board

Proactive Investors · 15 Oct 2026neutral

Lisata Therapeutics appointed biopharma finance executive Jeffrey Farrow to its board of directors. The appointment fills a newly created seat, expanding the board from seven members to eight.

Why it matters — LSTA watchers may note the addition of a finance executive to the board and the increase in board size.

Lisata Therapeutics Appoints Jeff Farrow to Board of Directors

GlobeNewsWire · 14 Oct 2026positive

Lisata Therapeutics appointed Jeff Farrow to its board of directors. The veteran biopharma CFO brings more than 15 years of public-company financial leadership and will join the Audit Committee.

Why it matters — The appointment adds an experienced financial leader to Lisata’s board and Audit Committee.

Lisata Therapeutics wins new US patent for pancreatic cancer drug

Proactive Investors · 8 Oct 2026positive

Lisata Therapeutics said the US Patent and Trademark Office granted it a Method of Use patent covering experimental drug certepetide for treating pancreatic cancer and other solid tumors.

Why it matters — The patent grant is relevant to LSTA watchers tracking intellectual-property developments around certepetide and its potential uses.

FAQ

Frequently asked questions about LSTA stock

What is the LSTA stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Lisata Therapeutics, Inc. have a median 12-month price target of $4, with estimates ranging from $4 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LSTA stock a buy right now?

Of the 2 analysts covering Lisata Therapeutics, Inc., 0 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lisata Therapeutics, Inc. 58 out of 100 across roughly 4,600 US stocks as at 13 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LSTA?

As at 13 Nov 2026, Lisata Therapeutics, Inc. ranks 58 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (89 of 100).

Will LSTA stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +222.6% from the last close, and Ticker Nerd's factor model ranks Lisata Therapeutics, Inc. 58 out of 100 as at 13 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LSTA stock forecast for 2030?

No analyst covering Lisata Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LSTA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.

How has LSTA stock performed over the past year?

Lisata Therapeutics, Inc. returned -40.1% over the 12 months to 13 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Lisata Therapeutics, Inc. do?

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing therapies for advanced solid tumors and other major diseases.

What is the latest news on LSTA?

The most recent item we track (GlobeNewsWire, 9 Nov 2026): "Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces MAR001 Reduces Triglycerides Without Worsening Glycemic Control in Phase 2b TYDAL-TIMI 78 Trial; Results Presented as AHA 2026 Late-Breaker and Published in The New England Journal of Medicine". Marea Therapeutics, a Lisata Therapeutics subsidiary, reported that Part A of the Phase 2b TYDAL-TIMI 78 trial met all objectives. MAR001 produced statistically significant placebo-adjusted triglyceride reductions of 39.1%–45.5% across three doses at Week 12, and up to 57.2% among participants with baseline triglycerides of at least 300 mg/dL.

Company

About Lisata Therapeutics, Inc.

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing therapies for advanced solid tumors and other major diseases. The company’s lead product candidate, certepetide, is designed to activate a novel uptake pathway that may improve the delivery and penetration of anti-cancer drugs within solid tumors. Lisata Therapeutics’ current work centers on oncology programs that evaluate certepetide in combination with existing cancer regimens across several solid tumor settings. The company also maintains research efforts in other disease areas through its broader development pipeline. Headquartered in Basking Ridge, New Jersey, Lisata Therapeutics plays a role in the biopharmaceutical market by advancing treatment approaches intended to enhance how established therapies reach tumor tissue.

CEO Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. · 21 employees · United States · https://www.lisata.com